Active Biotech Wins Approval to Resume Expanded Tasquinimod Myelofibrosis Trial

Active Biotech AB ( (SE:ACTI) ) has shared an update.

Active Biotech has received regulatory approval for protocol amendments to its clinical proof-of-concept study of tasquinimod in myelofibrosis, allowing the trial to resume patient recruitment. The study, led by MD Anderson Cancer Center, now features a dosing schedule aligned with prior prostate cancer trials and accommodates use with either ruxolitinib or momelotinib in combination cohorts.

The trial includes a monotherapy arm for patients who are refractory or intolerant to JAK2 inhibitors and a combination arm for those with suboptimal responses to existing JAK inhibitor therapy. By broadening the eligible patient population and increasing dosing flexibility, the updated design is intended to better assess tasquinimod’s potential role in treating this rare blood cancer, where there remains no approved therapy to reverse bone marrow fibrosis.

The most recent analyst rating on (SE:ACTI) stock is a Sell with a SEK0.04 price target. To see the full list of analyst forecasts on Active Biotech AB stock, see the SE:ACTI Stock Forecast page.

More about Active Biotech AB

Active Biotech AB is a Swedish biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical need and significant commercial potential. Its core programs include tasquinimod for myelofibrosis, laquinimod for non-infectious uveitis, and the partnered cancer immunotherapy naptumomab for advanced solid tumors.

YTD Price Performance: -17.39%

Average Trading Volume: 9,859,186

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK101.2M

For a thorough assessment of ACTI stock, go to TipRanks’ Stock Analysis page.